Gileads response to radceways patent: applied globally in 2016

category:Society
 Gileads response to radceways patent: applied globally in 2016


Gilead has developed remdesivir and has patents in the US, China and the rest of the world, Gilead said. In 2016, Geely applied for more patents in China and around the world for the application of remdesivir in coronavirus. In China, patent applications for coronavirus applications have yet to be approved.

We have noticed that Wuhan Virus Research Institute has applied for patent for the application of related drugs, gillid said However, it is too early to discuss any compulsory licensing or other types of licensing at this stage. We have not had any discussions with regulators about the production and supply costs or financial returns of Gilead. Our focus now is to confirm the potential therapeutic effect of remdesivir on the new coronavirus as soon as possible, speed up the production and supply, so as to meet the potential supply demand in the future, the company told first finance and economics

Gillid did not say whether it would challenge the patents of the Wuhan Institute of viruses. Gilead has no right to interfere with whether the Patent Office grants patents to Chinese researchers, the company said. The patent application of Wuhan Virus Research Institute was submitted more than three years after Gilead filed the application. The consideration of the application will integrate the current known knowledge of the synthetic drug and the patent under application. We cant comment on the details of the researchers patent application because the content of the patent application wont be published until 18 months later.

(function(){(window.slotbydup=window.slotbydup||[]).push({id:u5811557,container:ssp_5811557,async:true});})(); Previously, Wuhan Virus Research Institute said in a statement issued on February 4: for ridacivir, a drug that has not yet been listed in China and has intellectual property barriers, we declared Chinas invention patent (the use of anti-2019 new coronavirus) on January 21 in accordance with international practices and from the perspective of protecting national interests, and will go further through PCT (patent cooperation agreement) Into the worlds major countries. If relevant foreign enterprises intend to contribute to Chinas epidemic prevention and control, we agree that we will not require the implementation of the rights claimed in the patent for the time being if the country needs it. On the morning of February 6, the first financial reporter called Wang Manli, a researcher of Wuhan Virus Research Institute and the co-author of ridsiweis paper, and there was no answer; the email sent to the Institute on the evening of February 5 was also unresponsive. Source: First Financial Editor: Zhang Xianchao, nn9310

Previously, Wuhan Virus Research Institute said in a statement issued on February 4: for ridacivir, a drug that has not yet been listed in China and has intellectual property barriers, we declared Chinas invention patent (the use of anti-2019 new coronavirus) on January 21 in accordance with international practices and from the perspective of protecting national interests, and will go further through PCT (patent cooperation agreement) Into the worlds major countries. If relevant foreign enterprises intend to contribute to Chinas epidemic prevention and control, we agree that we will not require the implementation of the rights claimed in the patent for the time being if the country needs it.

On the morning of February 6, the first financial reporter called Wang Manli, a researcher of Wuhan Virus Research Institute and the co-author of ridsiweis paper, and there was no answer; the email sent to the Institute on the evening of February 5 was also unresponsive.